New drug combo shows promise for genetic subtype of leukemia
NCT ID NCT02632708
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests two new targeted drugs (AG-120 and AG-221) given alongside standard chemotherapy for people with a specific genetic form of acute myeloid leukemia (AML). The study includes about 153 adults with newly diagnosed AML that has an IDH1 or IDH2 mutation. The main goal is to check the safety of these combinations and find the best dose for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AG-120 or AG-221 (targeted therapy drugs) combined with standard chemotherapy (cytarabine, daunorubicin, idarubicin, mitoxantrone, etoposide)
- What this could lead to
- If successful, this could lead to a safer, more effective treatment option for people with a specific genetic subtype of AML, potentially improving outcomes.
- What could go wrong
- This is an early Phase 1 trial focused on safety, not yet on effectiveness. The drugs may cause side effects or not work better than standard therapy. Results may not apply to all AML patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML ARISING AFTER EXPOSURE TO GENOTOXIC INJURY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02114, United States
-
Erasmus MC
Rotterdam, 3075 EA, Netherlands
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Johns Hopkins University
Baltimore, Maryland, 21231, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Medical University of South Carolina - PPDS
Charleston, South Carolina, 29425-0001, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
UCLA Medical Center
Los Angeles, California, 90024, United States
-
Universitatsklinikum Ulm
Ulm, 89081, Germany
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
-
VU Medisch Centrum
Amsterdam, 1081 HV, Netherlands
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill targets rare gene mutation in Hard-to-Treat blood cancers
- Promising combo for IDH1 leukemia hits early snag – trial stopped
- New hope for older leukemia patients: drug combo aims for higher remission
- New drug combo aims to control rare leukemia without harsh chemo
- New drug cocktail aims to beat leukemia in patients too frail for standard chemo